91 results about "Pericyte" patented technology

Disclosed is a method for the prediction of the efficacy of a vascularization inhibitor. In the method, the anti-tumor effect of a vascularization inhibitor can be predicted by measuring the number of blood vessels surrounded by pericytes in a tumor and using the measurement value as a measure for the anti-tumor effect.

In one embodiment, the invention provides a pericyte having a marker pattern comprising CD146+, CD34−, and CD45−, wherein said pericyte is substantially isolated from cells that are CD146− or CD31+ or CD34+ or CD45+ or CD56+ or NG2− or CD133−. The invention also provides populations of such pericytes. In another embodiment, the invention provides a method for isolating a pericyte. In another embodiment, the invention provides a method for modeling tissue in vivo.

A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and/or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.

The present invention relates to methods, kits, compositions and uses thereof for treating cancer. In particular, the present invention relates to methods, kits, compositions and uses thereof for the treatment of metastatic cancer, the treatment of angiogenesis associated with metastatic cancer, inhibiting formation of vasculature associated with metastatic cancer, killing pericytes associated with metastatic cancer and killing cancer cells contiguous with tumour capillaries associated with metastatic cancer, comprising a killing agent conjugated to a protein, and wherein said killing agent conjugated to said protein binds to at least one cell associated with the metastatic cancer.

The present invention provides methods for growing and inducing perivascular cell differentiation of adipose tissue-derived stromal cells. The invention further provides methods for administering such adipose tissue-derived cells to a subject. The cells of the invention are useful for treating diseases, disorders, conditions, and injuries requiring new or enhanced angiogenesis, vascular remodeling, drug delivery, and tissue engineering.

In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.

A bicellular vascular population derived from human pluripotent stem cells (hPSCs) undergoes morphogenesis and assembly in a synthetic hydrogel. It is shown that hPSCs can be induced to co-differentiate into early vascular cells (EVCs) in a clinically-relevant strategy dependent upon Notch activation. These EVCs mature into ECs and pericytes, and self-organize to form vascular networks in an engineered matrix. Upon in vivo implantation, multicellular human vascular networks are functionally perfused. Thus, a derived bicellular population is exploited for its intrinsic self-assembly capability to create functional microvasculature in a deliverable matrix.

It is intended to provide a screening system for a centrally acting drug transported across the blood-brain barrier, a drug acting on the blood-brain barrier itself, or a drug transferred into the brain without being expected to centrally act. Moreover, another object of the present invention is to achieve pathogenesis analysis study or the screening in a diseased state by applying various diseased environments to this screening system. The present invention provides an in-vitro model of blood-brain barrier obtained by using a three-dimensional culture apparatus comprising: a culture solution; a plate holding the culture solution; and a filter immersed in the culture solution and placed in no contact with the inside bottom of the plate, the filter having plural pores of 0.35 to 0.45 μm in diameter, and by comprising: seeding primary cultured brain capillary endothelial cells onto the upper surface of the filter; seeding primary cultured brain pericytes onto the under surface of the filter; seeding primary cultured astrocytes onto the inside surface of the plate; and coculturing these cells in a normal culture solution.

Thus, provided herein are pericyte progenitor cells (e.g., isolated pericyte progenitor cells), methods for generating pericyte progenitors in clinically relevant numbers for various applications applying macromolecular crowding during cell culture, and methods of using the pericyte progenitor cells.

The present disclosure relates to fabricating sacrificial microfiber templates from any biocompatible and resorbable materials depending on the time needed for dissolving the microfiber template to free the endothelial tube with open lumen. Microfiber networks with distinct patterns and defined diameters initially serve as a template to support the growth of vascular cells (endothelial cells or their progenitor cells, or combined with mural cells such as pericytes) and then dissolve to form an empty endothelium lumen. The incorporation of sacrificial microfiber networks encapsulated with vascular cells into 3D cell-rich constructs allows for the creation of various vascularized tissues.

An application of a CD146 monoclonal antibody in detection and separation and identification of glioma perivascular cells. The CD146 monoclonal antibody is prepared from a hybridoma cell strain which is assigned the accession number of CCTCC No: C2016183. The CD146 monoclonal antibody 4F10 has excellent specificity and can accurately recognize tumor perivascular cells. In addition, the CD146 monoclonal antibody 4F10 can be used for flow cytometry sorting and detection of glioma-derived pericytes.

Low oxygen tension is a critical regulator of the developing or regenerating vasculature. The present invention is based on the determination that low oxygen tension during early stages of early vascular cell (EVC) derivation induces endothelial commitment and maturation of pluripotent stem cells. Inhibition of reactive oxygen species generation during the early stages of differentiation abrogates the endothelial inductive effects of the low oxygen environments. Methods of generating various types of cells from pluripotent stem cells (PSCs) are described, as well as compositions and methods of use thereof. In particular, generation of EVCs, bicellular vascular populations, early endothelial cells (ECs) and pericytes via culture in a low oxygen environment is described.

A method to construct an in-vitro human blood brain barrier (BBB) model is disclosed, which comprises steps: attaching suspension liquids of human brain vascular pericytes (HBVPs) and human astrocytes (HAs) by a ratio of 1:1, 1:2, or 1:6 to a bottom surface of a filter membrane of a culture dish to plant HBVPs and HAs on the bottom surface; filling a suspension liquid of human brain microvascular endothelial cells (HBMECs) into a top surface of the filter membrane to plant HBMECs on the top surface; placing the culture dish in a well plate containing a culture medium, and placing the well plate in a carbon-dioxide incubator; replacing the culture medium with a condition medium; and replacing the condition medium once daily for a plurality of days. Thereby is constructed an in-vitro human BBB model of high medical research availability.

An in vitro model system that guides the development of microvasculature, recapitulating the detailed organization of both its cellular and a-cellular components is established. Use of electrostretched fibrin microfibers enables both endothelial layer organization and co-culture of supporting perivascular (mural) cells such as vascular smooth muscle cells and pericytes. The fiber curvature affects the circumferential deposition of endothelial-produced ECM independently of cellular organization and induces deposition of higher quantities of vascular ECM proteins. Further, a luminal multicellular microvascular structure is disclosed.

The present invention provides methods for determining or identifying compounds that modulate the function of an isolated retinal pericyte or blood vessel, wherein a change in the contractile state of said pericyte or blood vessel is determined in the presence of a test compound, said change indicating that the test compound modulates the function of pericytes and/or blood vessels.

The invention discloses a construction method of an endothelial cell and pericyte co-culture model for researching tubulation. The method comprises the following steps: (1) digesting umbilical vein endothelial cells with trypsin to obtain umbilical vein endothelial single cells; (2) digesting pericytes into single cells of the pericytes by using trypsin, and then adding CFSE dye with the final concentration of 2-10 [mu]mol/L for staining to obtain stained pericytes; and (3) uniformly mixing the umbilical vein endothelial single cells and the stained pericytes according to the cell number ratio of (5-20):1, conducting culturing by using a bronchial epithelial cell culture medium, and observing the formation condition of the tube on a fluorescence microscope. According to the method disclosed by the invention, the influence of pericytes on the formation of endothelial cell tubes can be dynamically observed through a fluorescence microscope, the effect of human tumor pericytes on tumor blood vessels can be reflected through in-vitro experiments, and the method has good social and economic values.

The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord perivascular cells.

The invention relates to a mixed stem cell injection containing three vascular regeneration attributes. The mixed stem cell injection comprises Wharton jelly mesenchymal stem cells (WJMSCs), human umbilical artery adventitia periodontal cells (APCs) and human umbilical artery adventitia Flk-1 + cells. Umbilical cords abandoned by newborns are used as a material source; the method comprises the following steps: extracting Flk-1 + cells and umbilical artery peripheral cells APC from umbilical artery adventitia; the two cells provide two direct and specific precursor cells for vascular regeneration, and through the extracellular matrix components of the new blood vessel supplemented, updated and formed by the WJMSCs, a regeneration microenvironment for differentiation of the vascular precursor cells into the blood vessel under regulation and control of a vascular regeneration signal system is further formed. The three stem cells are mixed in proportion for an in-vitro culture experiment,and the result proves that the vascular net is successfully formed after in-vitro culture is performed for 13 days. The injection provided by the invention can be prepared into an injection for vascular regeneration, and is used for treating ischemic heart disease, ischemic stroke, ischemic peripheral vascular disease and other diseases.

The present disclosure provides methods for forming stable three-dimensional vascular structures, such as blood vessels and uses thereof. More specifically, the present disclosure provides methods for culturing differentiated endothelial cells that include an exogenous nucleic acid encoding ETV2 transcription factor on a matrix under conditions that express exogenous ETV2 protein in the endothelial cell to form stable three-dimensional artificial blood vessels without the use of a scaffold, pericytes or perfusion. The present disclosure also provides stable three-dimensional blood vessels that are capable of autonomously forming a functional three-dimensional vascular network, and uses thereof. In addition, the present disclosure includes methods for vascularizing an organoid and a decellularized organ by culturing the organoid or decellularized organ with endothelial cells that include an exogenous nucleic acid encoding ETV2 transcription factor under conditions that express exogenous ETV2 protein in the endothelial cell to vascularize the organoid or decellularized organ.

The invention discloses a neural crest-lineage pericyte derived from multi-potential stem cells and an induced differentiation method of the neural crest-lineage pericyte. The induced differentiationmethod comprises the following steps: dissociating the multi-potential stem cells to obtain single-cell suspension, inoculating the single-cell suspension into a matrigel-coated pore plate, and changing the suspension through an NCN2 culture medium each day; carrying out culturing for a certain period of time, carrying out digestion, and collecting cells; carrying out adherent culture on the collected cells, changing culture liquid into pericyte induced culture liquid, carrying out subculture, and detecting the cell phenotype of the pericyte. According to the induced differentiation method, the disadvantages of limited source of human cerebral vessel pericytes, and the heterogeneity and linkage heterogeniety of the pericytes derived from multi-potential stem cells obtained in other non-finite induction ways are solved, and the obtained neural crest-lineage pericyte has very strong blood vessel stabilizing capacity and contractility; and by virtue of a standardized induced differentiation procedure, cell populations obtained in different batches have good coherence.